{
  "risk_score_0_to_1": 0.15,
  "confidence_0_to_1": 0.90,
  "dominant_mechanisms": [
    {"mechanism": "mitochondrial_dysfunction", "score_0_to_1": 0.40},
    {"mechanism": "reactive_metabolite_formation", "score_0_to_1": 0.05},
    {"mechanism": "cholestasis_bsep_inhibition", "score_0_to_1": 0.10},
    {"mechanism": "immune_mediated_injury", "score_0_to_1": 0.15},
    {"mechanism": "oxidative_stress", "score_0_to_1": 0.20}
  ],
  "time_to_onset": "subacute_weeks_to_months",
  "dose_dependence": "minimal_dose_relationship",
  "reversibility": "reversible_if_early",
  "uncertainties": [
    "True incidence of metformin hepatotoxicity may be underestimated due to widespread use and attribution bias",
    "Whether mild transaminase elevations represent true hepatotoxicity or metabolic adaptation unclear",
    "Mechanism distinguishing rare hepatotoxic cases from millions of safe users poorly understood",
    "Potential confounding from NAFLD/NASH in diabetic populations complicates causality assessment"
  ],
  "citations": [
    "Desilets AR, et al. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother. 2008;42(6):817-826.",
    "Miralles-Linares F, et al. Metformin-induced hepatotoxicity. Diabetes Care. 2012;35(3):e21.",
    "Gough SC, et al. Efficacy and safety of a fixed-dose combination of alogliptin and metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2014;16(12):1291-1299."
  ]
}